Nxera Pharma Co., Ltd. Logo

Nxera Pharma Co., Ltd.

4565 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区赤坂9−7−2
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nxera Pharma Co., Ltd. is a pioneering Japanese biopharmaceutical company dedicated to revolutionizing medicine through advanced science and technology. With a mission to accelerate the development of life-changing therapies, Nxera focuses on creating innovative solutions that enhance patient care. The company is committed to pushing the boundaries of drug design, specifically through its expertise in structure-based methodologies. By forging strategic partnerships and pursuing groundbreaking discoveries, Nxera aims to bring forth the next generation of medical treatments. With a robust pipeline and a dedication to addressing unmet medical needs, Nxera Pharma is at the forefront of delivering better health outcomes for patients worldwide.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Nxera Pharma Co., Ltd.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-04-16 08:57
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:55
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:53
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 39.8 KB
2025-04-16 08:51
Regulatory News Service
臨時報告書
Japanese 32.4 KB
2025-03-26 08:42
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:41
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:40
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 40.4 KB
2025-03-26 08:38
Regulatory News Service
臨時報告書
Japanese 28.0 KB
2025-03-26 08:37
Regulatory News Service
内部統制報告書-第35期(2024/01/01-2024/12/31)
Japanese 23.8 KB
2025-03-26 08:36
Regulatory News Service
確認書
Japanese 8.6 KB
2025-03-26 08:35
Annual Report
有価証券報告書-第35期(2024/01/01-2024/12/31)
Japanese 1.3 MB
2025-02-14 07:47
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 38.2 KB
2025-02-14 07:46
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 38.2 KB
2025-02-14 07:45
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 36.4 KB
2024-08-09 09:10
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 41.7 KB

Automate Your Workflow. Get a real-time feed of all Nxera Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Nxera Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK